Director Clinical Quality and Compliance
HeartFlow
Director Clinical Quality and Compliance
HeartFlow
Non-invasive cardiac imaging to guide treatment
Heartflow is a medical technology company advancing the diagnosis and management of coronary artery disease, the #1 cause of death worldwide, using cutting-edge technology. The flagship product—an AI-driven, non-invasive cardiac test supported by the ACC/AHA Chest Pain Guidelines called the Heartflow FFRCT Analysis—provides a color-coded, 3D model of a patient’s coronary arteries indicating the impact blockages have on blood flow to the heart. Heartflow is the first AI-driven non-invasive integrated heart care solution across the CCTA pathway that helps clinicians identify stenoses in the coronary arteries (RoadMap™Analysis), assess coronary blood flow (FFRCT Analysis), and characterize and quantify coronary atherosclerosis (Plaque Analysis). Our pipeline of products is growing and so is our team; join us in helping to revolutionize precision heartcare.
Heartflow is a publicly traded company (HTFL) that has received international recognition for exceptional strides in healthcare innovation, is supported by medical societies around the world, cleared for use in the US, UK, Europe, Japan and Canada, and has been used for more than 750,000 patients worldwide.
The Director of Clinical Quality & Compliance is responsible for the strategic oversight, management, and execution of clinical quality assurance and regulatory compliance programs across pre-market and post-market clinical research initiatives. The role will work closely with internal Clinical Operations teams and cross-functional partners to support and monitor compliance, ensure adherence with FDA IDE requirements and Good Clinical Practice (GCP), and maintain inspection readiness across all studies, both internally managed and externally initiated or managed.
Job Responsibilities:
Skills Needed:
Educational Requirements & Work Experience:
A reasonable estimate of the base salary compensation range is $215,000 to $240,000, bonus, and equity. #LI-Hybrid
HeartFlow provides a non-invasive cardiac test that helps doctors visualize a patient’s coronary arteries to diagnose and plan treatment for heart disease. It uses a proprietary set of analyses—FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner—to create a detailed, patient-specific visualization from imaging data, enabling clinicians to assess blood flow and plaque without surgery. This approach reduces the need for invasive procedures, lowers risk for patients, and can cut costs for healthcare providers. Compared with traditional methods, HeartFlow offers validated, FDA-cleared tools that integrate multiple analyses into one platform, giving physicians a clearer, data-driven basis for diagnosis and treatment decisions. The company’s goal is to improve cardiovascular care by making safer, more efficient diagnosis and treatment planning widely available in hospitals and clinics around the world.
Explore more opportunities at HeartFlow